Navigation Links
Roka Bioscience Awarded AOAC-RI Certification for Atlas™ Salmonella Detection Assay
Date:3/22/2012

WARREN, N.J., March 21, 2012 /PRNewswire/ -- Roka Bioscience announced today that their Atlas Salmonella Detection Assay has received AOAC Performance Tested Methods(SM) certification from the AOAC Research Institute (AOAC-RI). The independent laboratory study was conducted by Silliker, Inc., as part of the AOAC-RI independent third-party validation process.

The Atlas Salmonella Detection Assay runs on the Atlas System, an innovative fully automated molecular instrument for the detection of pathogens in food and environmental samples. This instrument utilizes a simple three-step procedure—Enrich, Transfer, Automate—and is capable of processing over 300 samples in 8 hours. The system's continuous workflow and high throughput provides greater efficiency, flexibility, and dynamic scalability to meet the ever-increasing demands placed on food safety laboratories. Customer evaluations have demonstrated a reduction in direct labor costs with the Atlas System in side-by-side comparisons with leading competitive methods.

The initial menu for the Atlas System includes the Atlas Salmonella Detection Assay and the Atlas Listeria Detection Assay, which received AOAC-RI certification in January 2012. Additional assays are currently in development.

"AOAC-RI certification involves rigorous independent testing and reviews and is a critical performance-based validation," states Paul Thomas, CEO and President of Roka Bioscience. "Adding the Atlas Salmonella Assay to our menu of AOAC-RI-approved assays underscores our commitment to making the Atlas System and Atlas Detection Assays the ideal testing solution for food safety laboratories."

About AOAC-RI
The AOAC Research Institute (AOAC-RI) is a wholly owned subsidiary of AOAC INTERNATIONAL (AOAC) that administers AOAC's conformity assessment, including the AOAC Performance Tested Methods program. AOAC is a globally recognized, independent, not-for-profit standards developing association founded in 1884. AOAC serves the analytical community by engaging industry stakeholders to develop voluntary consensus standards for methods and providing analytical methods that demonstrate confidence in analytical results. For more information on the AOAC-RI and AOAC, visit the AOAC website at www.aoac.org.

Roka Bioscience
Roka Bioscience is a privately held company focused on developing and commercializing innovative solutions based on molecular technologies for the industrial markets. The company's scientific platform is based on proven, proprietary technologies used widely in clinical diagnostic testing and now being introduced into food safety and other industrial markets. Roka's current product line provides food safety professionals with a fully automated molecular pathogen detection solution that delivers rapid, accurate results and improved laboratory efficiencies. For more information, visit www.rokabio.com.

Contact:
Steve Sobieski
Chief Financial Officer
(908) 605-4621
ssobieski@rokabio.com


'/>"/>
SOURCE Roka Bioscience
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
2. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
3. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
4. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
5. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
6. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
7. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
8. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
9. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2017)... 2017  New York City-based market research firm Kalorama Information ... aware of.  From new products to new costs, to the ... recently completed study, Potential Pipeline Disruptors . ... 1.  Age-Driven Growth - True Impact Moment Arriving ... the impact the growing population and, to a more extreme ...
(Date:7/11/2017)... ROCKVILLE, Md. , July 11, 2017  The ... had estimated revenues of approximately $394.1 million in 2016.  ... a trend of solid growth, in particular as a ... oncology clinical practice, and the recent introduction of a ... the need for less-invasive testing of tumor biomarkers to ...
(Date:7/10/2017)... GAITHERSBURG, Md. , July 10, 2017 ... in non-animal test methods, is the recipient of a ... by the PETA International Science Consortium. The device, which ... be used to expose human lung cells to airborne ... lung. IIVS will use the VITROCELL® system for testing ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... “Kids aren't born knowing how to ... shoes,” says Suzanne Tucker, Founder of St. Louis-based positive education company Generation Mindful. To ... Kickstarter on Monday, July 21st. , The kit uses colorful, engaging and educational ...
(Date:7/21/2017)... CANADA (PRWEB) , ... July 21, 2017 , ... ... torn anterior cruciate ligament (ACL) offer patients improved quality of life five years ... for Sports Medicine’s Annual Meeting in Toronto, Ontario, Canada. The study followed ...
(Date:7/20/2017)... Boston, MA (PRWEB) , ... July 20, 2017 ... ... aggressive form of blood and bone marrow cancer that progresses rapidly without treatment. ... often recommended to reduce the chance of reoccurrence and relapse. With such ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... in which their iMedSecure™ comes included with each system installation. RMT’s iMedHD2™ ... to remote participants for real-time collaboration and immediate decision-making requirements. While never ...
Breaking Medicine News(10 mins):